Anti Estrogen Compounds (PCT)
Kalpa Pharmaceuticals
Arimixyl 1 mg
Product Information Compound Details
Active Substance Anastrozole Selective aromatase inhibitor
1 mg/tabletStrength 1 mg/tablet
Package 30 or 100 Tablets 30 mg or 100 mg total labeled content
Form Oral Tablet
Half-Life Approximately 46.8 Hours
Drug Class Aromatase Inhibitor
Manufacturer Kalpa Pharmaceuticals
Amount :
30 tabs
100 tabs
Shipping :
International
U.S. Domestic
Out of stock
- Overview
- Profile
- Usage
- Safety
- Shipping
- Storage
- FAQ
- Reviews
Product Overview
Arimixyl 1 mg by Kalpa Pharmaceuticals
Arimixyl 1 mg is an oral anastrozole tablet manufactured by Kalpa Pharmaceuticals and dosed at 1 mg per tablet, available in packs of 30 or 100 tablets.
Anastrozole Oral
Arimixyl 1 mg contains anastrozole, a potent and selective non-steroidal aromatase inhibitor. Anastrozole works by blocking the aromatase enzyme, which converts androgens such as testosterone into estrogen. This mechanism reduces circulating estrogen levels in the body. Anastrozole is FDA-approved for the treatment of hormone receptor-positive breast cancer in postmenopausal women.
In clinical research, anastrozole has been studied in males for conditions related to estrogen excess. A pharmacokinetic study in adolescent boys with gynecomastia found that anastrozole (1 mg daily) was rapidly absorbed, with a terminal half-life of 46.8 hours, and significantly increased testosterone/estradiol ratios. Exploratory analysis showed a reduction in breast area and volume in the study cohort. However, a separate double-blind trial in prostate cancer patients found that anastrozole did not significantly reduce the incidence of bicalutamide-induced gynecomastia, in contrast to tamoxifen which was effective.
In non-medical bodybuilding contexts, anastrozole is sometimes referenced to manage estrogenic side effects associated with aromatizable anabolic steroids, such as gynecomastia and water retention. The FDA has only approved anastrozole for breast cancer treatment, and there are no formal guidelines for its use in bodybuilding. Non-medical use falls outside approved indications and carries its own risks, including bone density loss and cardiovascular effects.
Key Benefits of Arimixyl 1 mg
- Potent and selective aromatase inhibitor
- Reduces circulating estrogen levels by blocking aromatase
- FDA-approved for hormone receptor-positive breast cancer
- Rapid oral absorption with a terminal half-life of approximately 46.8 hours
- Manufactured by Kalpa Pharmaceuticals with original packaging
Oral Formulation
Compressed Tablet
Arimixyl 1 mg is supplied as an oral compressed tablet containing 1 mg of anastrozole per unit, packaged in 30-tablet or 100-tablet formats by Kalpa Pharmaceuticals.
Product Profile
Anastrozole Profile
Anastrozole is a third-generation aromatase inhibitor characterized by potent and selective enzyme inhibition, non-steroidal structure, and a relatively long half-life. Its profile distinguishes it from other aromatase inhibitors such as exemestane and letrozole.
Selective Aromatase Inhibitor
Anastrozole is a nonsteroidal inhibitor of estrogen synthesis that selectively binds to and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex. Aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis. By inhibiting this enzyme, anastrozole reduces circulating estrogen levels.
The compound is rapidly absorbed orally, with a time to reach maximum concentration of approximately 1 hour and an apparent clearance of 1.54 liters/hour. The terminal half-life is 46.8 hours. These pharmacokinetic properties allow for once-daily dosing in clinical settings.
Anastrozole is approved for use in postmenopausal women with hormone receptor-positive breast cancer. It is not approved for use in premenopausal women, children, or males. In males, aromatase inhibitors have been investigated in clinical research for conditions such as gynecomastia and prostate cancer treatment side effects.
Release Profile
Long Half-Life
Anastrozole has a terminal half-life of approximately 46.8 hours in adolescent males and 50 hours in adult populations. This allows for once-daily dosing in clinical settings.
Arimixyl 1 mg vs Other Kalpa Preparations
Kalpa Pharmaceuticals offers several compounds referenced in non-medical bodybuilding contexts for managing hormonal side effects. The main distinctions involve mechanism of action and clinical profile.
For those comparing aromatase inhibitors, Aromaxyl (exemestane) is a steroidal aromatase inhibitor that works through a different mechanism. Letroxyl (letrozole) is a non-steroidal aromatase inhibitor with a different potency profile. For selective estrogen receptor modulators, Nolvaxyl 20 mg (tamoxifen) and Clomixyl 50 mg (clomiphene) work by blocking estrogen receptors rather than inhibiting estrogen production.
Dosage & Usage
Arimixyl 1 mg Dosage & Usage
The information below is provided for educational reference only. Anastrozole is a prescription medication; medical use requires appropriate diagnosis, clinical supervision, and ongoing monitoring. The FDA has only approved anastrozole for breast cancer treatment. Non-medical use falls outside approved indications.
Typical Dosage Ranges
In FDA-approved medical use, the recommended dose of anastrozole is one 1 mg tablet taken once daily for the treatment of hormone receptor-positive breast cancer in postmenopausal women. In clinical research in adolescent males with gynecomastia, anastrozole 1 mg daily was administered for 6 months. In non-medical bodybuilding contexts, anastrozole is sometimes referenced at 0.5 mg twice weekly, though such use falls outside approved indications and the FDA has not established guidelines for this purpose.
| Use Case | Common Reference Range | Frequency |
|---|---|---|
| Medical (breast cancer) | 1 mg per day | Once daily |
| Clinical research (gynecomastia) | 1 mg per day | Once daily for 6 months |
| Non-medical (bodybuilding) | 0.5 mg per dose | Twice weekly |
Stacking & Cycle Considerations
In non-medical bodybuilding contexts, anastrozole is sometimes referenced alongside aromatizable anabolic steroids to manage estrogenic side effects. The rationale involves reducing the conversion of testosterone to estrogen, which can help prevent gynecomastia and water retention associated with high estrogen levels.
However, the FDA has not approved anastrozole for this purpose, and there are no formal guidelines for its use in bodybuilding. Excessive estrogen suppression can lead to its own side effects, including joint pain and potentially negative effects on lipid profiles and bone density.
Managing Side Effects
Anastrozole is associated with several potential side effects, including hot flashes, asthenia, arthritis, pain, arthralgia, hypertension, depression, nausea, rash, osteoporosis, fractures, back pain, insomnia, headache, and peripheral edema. Decreases in bone mineral density may occur, and bone mineral density monitoring is recommended. Increases in total cholesterol may also occur.
In women with pre-existing ischemic heart disease, an increased incidence of ischemic cardiovascular events occurred with anastrozole use compared to tamoxifen. Blood pressure, lipid profiles, and bone density should be monitored during any use.
Post-Cycle Therapy (PCT)
Anastrozole is not a selective estrogen receptor modulator (SERM) and is not typically used as a primary PCT agent. In non-medical bodybuilding contexts, PCT protocols commonly reference SERMs such as Nolvaxyl 20 mg (tamoxifen) or Clomixyl 50 mg (clomiphene) to support recovery of endogenous testosterone production. Anastrozole may be referenced in some protocols for managing estrogen rebound, but medical guidance is strongly advised.
Important
Individual Response Varies
Dosing strategies and support protocols should be adjusted based on experience level, health status, and bloodwork where possible. The information above is for educational reference and does not constitute medical advice.
Safety & Information
Anastrozole Safety Information
Anastrozole is a prescription medication with significant effects on estrogen biosynthesis, bone mineral density, and cardiovascular risk markers. Medical use requires appropriate diagnosis, clinical supervision, and ongoing monitoring.
Important Safety Information
Anastrozole is indicated for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer, and treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. It is not approved for use in premenopausal women, children, or males.
Non-medical use of anastrozole falls outside approved indications and can expose individuals to risks including bone density loss, cardiovascular events, and lipid profile changes.
Important
Non-Medical Use
Anastrozole is a prescription medication. Non-medical use for bodybuilding or performance enhancement is not approved by the FDA and is associated with serious health risks including bone loss and cardiovascular events.
Potential Adverse Effects
In the early breast cancer (ATAC) study, the most common side effects (occurring with an incidence of ≥10%) in women taking anastrozole included hot flashes, asthenia, arthritis, pain, arthralgia, pharyngitis, hypertension, depression, nausea and vomiting, rash, osteoporosis, fractures, back pain, insomnia, headache, peripheral edema, and lymphedema.
Decreases in bone mineral density may occur, and bone mineral density monitoring is recommended. Increases in total cholesterol may occur, and cholesterol monitoring is recommended. In women with pre-existing ischemic heart disease, an increased incidence of ischemic cardiovascular events occurred with anastrozole use compared to tamoxifen.
Other reported adverse events include hepatobiliary events such as increases in alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, gamma-GT, and bilirubin; hepatitis; rash including mucocutaneous disorders; allergic reactions including angioedema, urticaria, and anaphylaxis; and myalgia, trigger finger, and hypercalcemia.
Conditions Requiring Medical Evaluation
Anastrozole is contraindicated in patients with demonstrated hypersensitivity to anastrozole or any excipient. It may cause fetal harm, and effective contraception is advised for females of reproductive potential.
Pre-existing ischemic heart disease, osteoporosis, high cholesterol levels, and liver problems require careful evaluation and monitoring before and during anastrozole use.
Monitoring During Therapy
Medically supervised anastrozole therapy may involve monitoring of bone mineral density due to the risk of decreases. Cholesterol monitoring is recommended due to potential increases in total cholesterol. In patients with pre-existing ischemic heart disease, cardiovascular monitoring is advised.
Any use of anastrozole should be accompanied by appropriate monitoring and medical supervision where possible.
Product Care
Storage & Handling
Store in a cool, dry place away from direct light and moisture. Keep tablets in the original packaging until use. Keep out of reach of children.
Further Safety Information
Shipping & Authenticity
Shipping & Product Authenticity
Arimixyl 1 mg is supplied through the official Kalpa Pharmaceuticals distribution chain and shipped in original manufacturer packaging with discreet, privacy-focused handling.
USA Domestic 3–5 business days
International 10–15 business days
Order Processing 24–48 business hours
Tracking Provided after dispatch
Direct Supply
Discreet Delivery & Original Packaging
The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details. Products are supplied through the official Kalpa Pharmaceuticals distribution chain.
What to Expect
- Orders are processed after payment confirmation
- USA Domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity Verification
To verify your Arimixyl 1 mg product, use the security code on the packaging and cross-check it on the Kalpa official site. Original Kalpa Pharmaceuticals presentation and packaging help reinforce product legitimacy and buyer confidence.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Storage
Arimixyl 1 mg Storage
Proper storage conditions help preserve tablet integrity and stability throughout shelf life.
Recommended Conditions
Store Arimixyl 1 mg in a cool, dry place away from excessive heat, moisture, and direct light. Maintaining stable conditions helps preserve the integrity of the tablets.
Keep the tablets in their original packaging until use. Do not use if the packaging is damaged or if the tablets appear abnormal in color or texture.
Keep out of reach of children. Follow proper handling practices for oral medications.
Quick Reference
Do & Don't
- Do store in a cool, dry place
- Do keep in original packaging
- Do inspect tablets before use
- Don't expose to direct sunlight
- Don't store in humid environments
- Don't use if packaging is compromised
Frequently Asked Questions
Arimixyl 1 mg FAQ
Answers to common questions about Arimixyl 1 mg, anastrozole, dosing, side effects, and product specifications.
What is Arimixyl 1 mg used for?
Arimixyl 1 mg contains anastrozole, which is FDA-approved for the treatment of hormone receptor-positive breast cancer in postmenopausal women. In clinical research, it has been studied in males for conditions such as gynecomastia. In non-medical bodybuilding contexts, it is sometimes referenced to manage estrogenic side effects of aromatizable anabolic steroids, though such use falls outside approved indications.
How often should Arimixyl 1 mg be taken?
In FDA-approved medical use, anastrozole is taken as one 1 mg tablet once daily. In non-medical bodybuilding contexts, it is sometimes referenced at 0.5 mg twice weekly, though such use falls outside approved indications and there are no formal guidelines for this purpose.
Does Arimixyl 1 mg require PCT?
Anastrozole is not a selective estrogen receptor modulator (SERM) and is not typically used as a primary PCT agent. In non-medical bodybuilding contexts, PCT protocols commonly reference SERMs such as Nolvaxyl 20 mg or Clomixyl 50 mg to support recovery. Anastrozole may be referenced in some protocols for managing estrogen rebound, but medical guidance is strongly advised.
What does anastrozole do?
Anastrozole is a nonsteroidal inhibitor of estrogen synthesis that selectively binds to and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex. Aromatase catalyzes the conversion of androgens such as testosterone into estrogens. By inhibiting this enzyme, anastrozole reduces circulating estrogen levels in the body.
How long does anastrozole take to work?
Anastrozole is rapidly absorbed orally, with a time to reach maximum concentration of approximately 1 hour. In a clinical study, significant increases in testosterone/estradiol ratios were observed after 14 days of daily dosing. The terminal half-life is 46.8 hours.
Is anastrozole the best aromatase inhibitor?
There is no single aromatase inhibitor that is universally best. Anastrozole is a potent and selective non-steroidal inhibitor. Other aromatase inhibitors such as Aromaxyl (exemestane) and Letroxyl (letrozole) have different structures and potency profiles. The appropriate choice depends on the clinical context and individual factors.
What is the difference between anastrozole and tamoxifen?
Anastrozole is an aromatase inhibitor that reduces estrogen production by blocking the aromatase enzyme. Tamoxifen is a selective estrogen receptor modulator (SERM) that blocks estrogen receptors rather than reducing estrogen production. In a clinical trial comparing the two for preventing bicalutamide-induced gynecomastia, tamoxifen was effective while anastrozole did not significantly reduce incidence.
What is the difference between anastrozole and exemestane?
Anastrozole is a non-steroidal, reversible aromatase inhibitor. Exemestane is a steroidal, irreversible aromatase inhibitor. Both are used in clinical settings for estrogen suppression, but their mechanisms and side effect profiles differ. Anastrozole is available as Arimixyl 1 mg while exemestane is available as Aromaxyl.
Is 1 mg of anastrozole a lot?
A 1 mg tablet represents the standard FDA-approved daily dose for breast cancer treatment. In non-medical bodybuilding contexts, doses are sometimes referenced at 0.5 mg twice weekly, which represents a lower cumulative weekly dose. Even at lower doses, anastrozole can significantly suppress estrogen levels and carries risks including bone density loss and cardiovascular effects.
What strength is Arimixyl 1 mg?
Arimixyl 1 mg is labeled at 1 mg of anastrozole per tablet. It is supplied in packs of 30 or 100 tablets.
Can anastrozole cause belly fat?
Weight gain and appetite changes have been reported as potential side effects of anastrozole. However, the relationship between anastrozole and specific fat distribution patterns such as belly fat is not well characterized in clinical literature. Changes in body composition should be discussed with a qualified healthcare professional.
Is Arimixyl 1 mg lab tested?
Laboratory testing information for Arimixyl 1 mg is not currently available in this product listing. Kalpa Pharmaceuticals products are manufactured under pharmaceutical-grade conditions, but independent lab reports are not published for this specific product at this time.
Related Offers
Kalpa Pharmaceuticals LTD, India
Product Information Compound Details
Active Substance Exemestane Irreversible steroidal aromatase inhibitor
25 mg/tabletStrength 25 mg/tablet
Package 30 Tablets 750 mg total labeled content
Form Oral Tablet
Half-Life Approximately 24 Hours
Drug Class Aromatase Inhibitor
Manufacturer Kalpa Pharmaceuticals
Kalpa Pharmaceuticals LTD, India
Product Information
Compound Details
Active Substance
Clomiphene Citrate
Selective estrogen receptor modulator
50 mg/tablet
Strength
50 mg/tablet
Package
30 or 100 Tablets
1,500 mg or 5,000 mg total labeled content
Form
Oral Tablet
Half-Life
Approximately 5–7 Days
Drug Class
Selective Estrogen Receptor Modulator
Manufacturer
Kalpa Pharmaceuticals
Kalpa Pharmaceuticals LTD, India
Product Information Compound Details
Active Substance Letrozole Non-steroidal aromatase inhibitor
2.5 mg/tabletStrength 2.5 mg/tablet
Package 30 Tablets 75 mg total labeled content
Form Oral Tablet
Half-Life Approximately 2 Days
Drug Class Aromatase Inhibitor
Manufacturer Kalpa Pharmaceuticals
Kalpa Pharmaceuticals LTD, India
Product Information
Compound Details
Active Substance
Tamoxifen Citrate
Selective estrogen receptor modulator
20 mg/tablet
Strength
20 mg/tablet
Package
30 or 100 Tablets
600 mg or 2,000 mg total labeled content
Form
Oral Tablet
Half-Life
Approximately 5–7 Days
Drug Class
Selective Estrogen Receptor Modulator
Manufacturer
Kalpa Pharmaceuticals
April 12, 2019
Kept my estrogen and bloat in check to great extent. Nips never went puffy. Didn't notice any gyno or estrogen related sides except a little bloat which went away quickly.